Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + vinorelbine (Cancer Institute and Hospital, Chinese Academy of Medical Sciences)
- Development stage
- Unknown
- Lead developer
- National Cancer Center Korea
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A sequential chemotherapy regimen consisting of gemcitabine followed by vinorelbine, specifically investigated by the National Cancer Center, Korea, for the treatment of metastatic or recurrent breast cancer. Gemcitabine is a nucleoside metabolic inhibitor that functions as a pyrimidine antimetabolite, inhibiting DNA synthesis by targeting ribonucleoside-diphosphate reductase and being incorporated into DNA. Vinorelbine is a semi-synthetic vinca alkaloid that inhibits mitosis by binding to tubulin and preventing microtubule assembly. This sequential approach was evaluated in a Phase II clinical trial to compare its efficacy and safety profile against concurrent combination therapy in patients previously treated with anthracyclines and taxanes.
- Brand names
- GemzarNavelbine
- Other names
- Sequential gemcitabine and vinorelbineGV regimenSequential-National Cancer Center, Korea-breast cancer
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gemcitabine + vinorelbine (Cancer Institute and Hospital, Chinese Academy of Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + vinorelbine (Cancer Institute and Hospital, Chinese Academy of Medical Sciences).